Targeting novel sites on reverse transcriptase for HIV treatment and prevention

针对逆转录酶的新位点治疗和预防艾滋病毒

• 批准号: nhmrc : 1119940
• 负责人: A/Pr Nicolas Sluis-Cremer
• 金额: $ 60.33万
• 依托单位: Macfarlane Burnet Institute for Medical Research and Public Health
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-novel-sites-treatment-prevention/946396
• 关键词: Targeting; novel; sites; reverse; transcriptase

HIV/AIDS remains a major global threat with 37 million individuals living with HIV in 2014. Antiretroviral drugs have transformed HIV from a death sentence into a chronic disease. Public health organisations recommend dramatic scale up of drugs for HIV treatment and prevention. However, a major threat is that drug options will be exhausted due to drug resistance and toxicity. The major aim of this study is to undertake fundamental studies to advance the development of a new HIV drug class.

艾滋病毒/艾滋病仍然是一个主要的全球威胁，2014年有3700万艾滋病毒携带者。抗逆转录病毒药物已经将艾滋病毒从死刑转变为慢性病。公共卫生组织建议大幅增加艾滋病毒治疗和预防药物的规模。然而，一个主要的威胁是，由于耐药性和毒性，药物选择将耗尽。这项研究的主要目的是进行基础性研究，以推动开发一种新的艾滋病毒药物类别。